A phosphoramidate‐based prostate‐specific membrane antigen‐targeted SPECT agent
- 5 October 2011
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 72 (8) , 904-912
Abstract
BACKGROUND Prostate‐specific membrane antigen (PSMA) remains an active target for imaging and therapeutic applications for prostate cancer. METHODS In the present study, an irreversible phosphoramidate inhibitor, CTT‐54 (IC50 = 14 nM), has been modified to deliver 99mTc‐(CO)3‐DTPA as a SPECT imaging payload to PSMA+ cells in vivo and in vitro. Percent uptake, competitive binding, and internalization will evaluate the imaging agent in vitro. Preliminary biodistribution and imaging will be utilized for in vivo evaluation. RESULTS In vitro studies demonstrate that the radiotracer 99mTc‐(CO)3‐DTPA‐CTT‐54 exhibits increasing cellular uptake in the PSMA+ LNCaP cells over time. More importantly, it was found that 99mTc‐(CO)3‐DTPA‐CTT‐54 is rapidly internalized into LNCaP cells, presumably through the PSMA enzyme‐inhibitor complex. In a pilot biodistribution study, increasing accumulation of the radiotracer in LNCaP xenografts was observed from 2 to 4 hr and significant clearance from non‐target tissues. CONCLUSIONS While DTPA may not represent the ideal chelate structure for 99mTc(CO)3, the data provides proof‐of‐concept support for the development of a next‐generation phosphoramidate‐based PSMA inhibitor‐conjugates for use as SPECT imaging agents. Prostate 72:904–912, 2012.Keywords
Funding Information
- Washington State Life Sciences Discovery Fund (LSDF 08-012374880)
This publication has 31 references indexed in Scilit:
- Assessment of an 18F-Labeled Phosphoramidate Peptidomimetic as a New Prostate-Specific Membrane Antigen–Targeted Imaging Agent for Prostate CancerJournal of Nuclear Medicine, 2009
- Radiohalogenated Prostate-Specific Membrane Antigen (PSMA)-Based Ureas as Imaging Agents for Prostate CancerJournal of Medicinal Chemistry, 2008
- Synthesis and Evaluation of Technetium-99m- and Rhenium-Labeled Inhibitors of the Prostate-Specific Membrane Antigen (PSMA)Journal of Medicinal Chemistry, 2008
- Cell‐Surface labeling and internalization by a fluorescent inhibitor of prostate‐specific membrane antigenThe Prostate, 2008
- Vascular Targeted Therapy With Anti–Prostate-Specific Membrane Antigen Monoclonal Antibody J591 in Advanced Solid TumorsJournal of Clinical Oncology, 2007
- Microfluidic System for Studying the Interaction of Nanoparticles and Microparticles with CellsAnalytical Chemistry, 2005
- In vivo cancer targeting and imaging with semiconductor quantum dotsNature Biotechnology, 2004
- Annual report to the nation on the status of cancer, 1975–2001, with a special feature regarding survivalCancer, 2004
- 11C-MCG: Synthesis, Uptake Selectivity, and Primate PET of a Probe for Glutamate Carboxypeptidase II (NAALADase)Molecular Imaging, 2002
- Detection and characterization of the prostate‐specific membrane antigen (PSMA) in tissue extracts and body fluidsInternational Journal of Cancer, 1995